

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 May 2018 (03.05.2018)



(10) International Publication Number
WO 2018/081367 A1

(51) International Patent Classification:

A61K 38/12 (2006.01) C07K 14/575 (2006.01)
A61K 38/22 (2006.01) C07K 14/46 (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:

PCT/US2017/058451

(22) International Filing Date:

26 October 2017 (26.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/413,586 27 October 2016 (27.10.2016) US
62/413,613 27 October 2016 (27.10.2016) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant: MACIELAG, Mark [US/US]; 1400 McKean
Road, Spring House, PA 19477 (US).

(72) Inventors: MACIELAG, Mark; 1400 McKean Road,
Spring House, PA 19477 (US). PATCH, Raymond, J.;
1400 McKean Road, Spring House, PA 19477 (US).
ZHANG, Rui; 1400 McKean Road, Spring House, PA
19477 (US). CASE, Martin A.; 3210 Merryfield Row,
San Diego, CA 92121 (US). WALL, Mark; 1400 McKean
Road, Spring House, PA 19477 (US). ZHANG, Yue-Mei;
1400 McKean Road, Spring House, PA 19477 (US).

(74) Agent: BARANIAK, Andrew, P. et al.; Panitch Schwarze
Belisario & Nadel LLP, Two Commerce Square, 2001 Mar-
ket Street, Suite 2800, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS



I

(57) Abstract: The present invention comprises compounds of Formula I wherein: Z₄, Z₇, Z₉, Z₁₁, Z₂₂, Z₂₃, Z₂₆, Z₃₀, Z₃₄, Z₃₅, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.



WO 2018/081367 A1